Enveric Biosciences, Inc.
Enveric Biosciences, Inc.
CAMBRIDGE, MA
Loading...
Price History
Market Data
| Market Cap | 336,330.49 |
| P/E Ratio | - |
| P/B Ratio | 0.08 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | - |
| Current Ratio | 5.38 |
| Currency | USD |
Key Financial Metrics
-
Revenue
-8.77M
Net Income
-
EPS (Diluted)
-14.81M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-8.57M
Returns & Efficiency
Return on Assets (ROA)
-172.1%
Return on Equity (ROE)
-210.0%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
5.10M
Total Debt
-
Debt to Equity
-
Current Ratio
5.38
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | CAMBRIDGE, MA |
| Fiscal Year | 2025 |
Peers
LILLY ELI & CO
LLY
935.08B
P/E: --
ELI LILLY & CO
LLY
935.08B
P/E: --
539.91B
P/E: --
ABBVIE INC.
ABBV
363.36B
P/E: --
BEIGENE, LTD.
BEIGF
306.50B
P/E: 632.4
BEONE MEDICINES LTD.
BEIGF
306.50B
P/E: 632.4
281.33B
P/E: --
MERCK & CO. INC.
MRK
281.33B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$336.33K
P/E Ratio (TTM)-
Price to Book0.08
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-210.0%
ROA-172.1%
Leverage & Liquidity
Debt to Equity-
Current Ratio5.38
Total Debt-
Total Assets$5.10M
Stockholders' Equity$4.18M
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$-8.77M
Net Income$-8.77M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-14.81M
Cash & Equivalents$4.68M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 245 FIRST STREET RIVERVIEW II 18TH FLOOR CAMBRIDGE, MA 02142 |
| Phone | N/A |
| Incorporated | DE, US |
| EIN | 954484725 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 108,319.00 |
| Stockholders' Equity | $4.18M |
| Cash & Equivalents | $4.68M |
Recent Filings
View All
D
D Filing
SEC regulatory filing
Filed: 2026-05-04
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-30
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-30
Local
EFFECT
Effectiveness Notice
Notice of effectiveness
Filed: 2026-04-29
Local
424B3
Prospectus (Rule 424b3)
Prospectus filed under Rule 424(b)(3)
Filed: 2026-04-29
Local
S-3
Shelf Registration
Short-form registration for seasoned issuers
Filed: 2026-04-23
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-20
Local
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-14
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-14
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-14
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-27
Local
424B3
Prospectus (Rule 424b3)
Prospectus filed under Rule 424(b)(3)
Filed: 2026-02-18
Local
EFFECT
Effectiveness Notice
Notice of effectiveness
Filed: 2026-02-17
Local
D
D Filing
SEC regulatory filing
Filed: 2026-02-11
Local
S-1
IPO Registration
Registration statement for initial public offering
Filed: 2026-02-10
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | Enveric Biosciences, Inc. |
| Ticker | ENVB |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | CAMBRIDGE, MA |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 336,330.49 |
| Revenue | - |
| Net Income | -8.77M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | - |
| ROE | -210.0% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...